Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAs/PLAs LACKING FINANCIAL DISCLOSURE INFORMATION WOULD BE REFUSED FILING

This article was originally published in The Tan Sheet

Executive Summary

NDAs/PLAs LACKING FINANCIAL DISCLOSURE INFORMATION WOULD BE REFUSED FILING under an FDA proposed rule on financial disclosure for clinical investigators, FDA Deputy Commissioner for External Affairs Carol Scheman said at the agency's Science Board meeting on Feb. 24. "If a firm refuses to certify or to disclose [financial arrangements]...we would refuse to file the application. We will not accept an application without a certification or a disclosure," Scheman said.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082530

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel